Abstract 5914
Background
The case for investing in better integrated mental health provision and training in cancer care is compelling. Mental health co-morbidity in cancer and end of life care is very common, poorly recognized, and leads to distress and loss of functioning. The recent SMaRT oncology trials, (Walker et al., 2014) have demonstrated that up to 73% of cancer patients with depression receive no evidence-based treatment for their depression. Standardized mortality ratio (SMR) for completed suicide in the cancer patient is four to seven times that of the matched population, (Robinson et al., 2009; Robson et al ., 2010). The increased awareness of co-morbid mental health conditions have impacted upon and influenced the cancer world. Yet, despite the plethora of research and policy advocating for better mental health provision for cancer patients, there is still a lack of recognition of the importance of assessing and managing co-morbid mental health in cancer patients.
Methods
The authors designed a one-day simulation based training programme using trained actors portraying cancer journeys, from diagnosis to end of life, with a number of different and relevant mental health co-morbidities. Inter-professional participants (n = 75) filled questionnaires both before and after the intervention (the simulation programme). The questionnaires consisted of multiple choice questions assessing knowledge of mental health co-morbidity in the cancer patient, and confidence (self- rated 1-5 Likert scales).
Results
Statistical t test analysis of pre v post intervention scores (n = 75) revealed highly statistically significant imrpovements to participants’ clinical knowledge (p < 0.0001) and confidence (p < 0.0001) as a result of the simulation intervention.
Conclusions
This study demonstrates that an innovative simulation programme has been evaluated as highly effective in improving knowledge and confidence of inter-professional learners at managing mental health co-morbidity in cancer patients. More research in this educational modality is welcomed in training clinicians.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Fernando.
Funding
Health Education England.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
860 - Dose differential modulation of the autophagic behavior of estrogen expressing breast carcinoma cells
Presenter: Mariam Fouad
Session: Poster Display session 1
Resources:
Abstract
2304 - Synthetic peptide of tumor–associated antigen L6 formulated with polymer-based adjuvant enhances anti-tumor effects in mice
Presenter: Shih-jen Liu
Session: Poster Display session 1
Resources:
Abstract
4419 - Improving detection level of somatic mosaicism in neurofibromatosis type 1
Presenter: Kristina Karandasheva
Session: Poster Display session 1
Resources:
Abstract
5283 - Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship of ABN401, a highly selective Met inhibitor, in gastric and non-small-cell lung cancer models
Presenter: JooSeok Kim
Session: Poster Display session 1
Resources:
Abstract
5488 - Transcription factors of Snail family in the regulation of resistance of breast cancer cells to hypoxic conditions
Presenter: Alvina Khamidullina
Session: Poster Display session 1
Resources:
Abstract
5417 - Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumour cells
Presenter: Liliana Mendonça
Session: Poster Display session 1
Resources:
Abstract
5494 - Identification of novel and known FGFR gene fusions in Chinese non-small cell lung cancer
Presenter: Weixin Zhao
Session: Poster Display session 1
Resources:
Abstract
3412 - WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients.
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 1
Resources:
Abstract
1815 - Leukocytosis as a negative prognostic factor in patients with lung cancer: Which subpopulation of leukocytes is responsible?
Presenter: Filip Kohutek
Session: Poster Display session 1
Resources:
Abstract
5022 - Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients
Presenter: Sergi Clavé
Session: Poster Display session 1
Resources:
Abstract